Zynerba Reports Positive Results for ZYN002 Cannabidiol Gel in Phase 1 Studies

Medical Device Investing

ZYN002 CBD gel was shown to be safe and well-tolerated across range of doses tested in healthy subjects and adult epilepsy patients with focal seizures
No impairment in cognitive performance or changes in psychological health were observedDEVON, Pa., Dec. 05,

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced additional results from Phase 1 randomized, double-blind, placebo-controlled single and multiple ascending dose studies of ZYN002 cannabidiol (CBD) gel. These results, which assessed safety, tolerability, and effects on cognition and mood, of ZYN002 CBD gel in both healthy adults and adult epilepsy patients with focal seizures, were reported at

... read more at: http://investingnews.com/daily/life-science-investing/medical-device-investing/zynerba-positive-results-zyn002-cannabidiol-gel-phase-1-studies/